<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Porphyria cutanea tarda and hepatoerythropoietic porphyria: Pathogenesis, clinical manifestations, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Porphyria cutanea tarda and hepatoerythropoietic porphyria: Pathogenesis, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Porphyria cutanea tarda and hepatoerythropoietic porphyria: Pathogenesis, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ashwani K Singal, MD, MS, FACG, FAASLD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karl E Anderson, MD, FACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert T Means, Jr, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4527356"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The porphyrias are metabolic disorders caused by altered activity of enzymes in the heme biosynthetic pathway. </p><p>Porphyria cutanea tarda (PCT; previously called symptomatic porphyria, chemical porphyria, toxic porphyria) is the most common type of porphyria. PCT was named by Waldenström in 1937 to emphasize the predominant cutaneous manifestations and relatively late onset of disease [<a href="#rid1">1</a>]. An earlier name for PCT was chronic hematoporphyria (assigned by Günther in 1911) [<a href="#rid2">2</a>]. PCT is caused by deficient activity of uroporphyrinogen decarboxylase (UROD) in the liver, with heterozygosity for a pathogenic variant in <em>UROD</em> sometimes contributing; hepatoerythropoietic porphyria (HEP), an extremely rare condition, is caused by biallelic pathogenic <em>UROD</em> variants.</p><p>This topic review discusses the pathogenesis, clinical manifestations, and diagnostic evaluation for PCT and HEP.</p><p>Management and prognosis of PCT and HEP are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/101414.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis"</a>.)</p><p>Additional topic reviews discuss the other cutaneous, neurovisceral, and combined cutaneous/neurovisceral porphyrias:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous</strong> – (See  <a class="medical medical_review" href="/z/d/html/7102.html" rel="external">"Congenital erythropoietic porphyria"</a> and  <a class="medical medical_review" href="/z/d/html/7125.html" rel="external">"Erythropoietic protoporphyria and X-linked protoporphyria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurovisceral</strong> – (See  <a class="medical medical_review" href="/z/d/html/7096.html" rel="external">"Acute intermittent porphyria: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7142.html" rel="external">"Acute intermittent porphyria: Management"</a> and  <a class="medical medical_review" href="/z/d/html/7095.html" rel="external">"ALA dehydratase porphyria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combined cutaneous and neurovisceral</strong> – (See  <a class="medical medical_review" href="/z/d/html/7126.html" rel="external">"Variegate porphyria"</a> and  <a class="medical medical_review" href="/z/d/html/7100.html" rel="external">"Hereditary coproporphyria"</a>.)</p><p></p><p>An overview of porphyrias is also presented separately. (See  <a class="medical medical_review" href="/z/d/html/7101.html" rel="external">"Porphyrias: An overview"</a>.)</p><p class="headingAnchor" id="H2231119"><span class="h1">DISEASE CLASSIFICATION</span><span class="headingEndMark"> — </span>PCT and HEP are cutaneous porphyrias, both due to deficient activity of the heme biosynthetic enzyme uroporphyrinogen decarboxylase (UROD) in the liver [<a href="#rid3">3</a>]. They cause blistering skin lesions as the predominant clinical manifestation; neurovisceral attacks do not occur.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCT</strong> – PCT is caused by acquired inhibition of hepatic UROD to approximately &lt;20 percent of normal, which occurs in the presence of iron and a variable combination of acquired factors (alcohol, smoking, hepatitis C, estrogens, human immunodeficiency virus [HIV] infection). </p><p></p><p class="bulletIndent1">Genetic factors are present in some patients; these may include heterozygosity for<em> </em>a pathogenic variant in the<em> UROD</em> gene, which predisposes to the disease by reducing UROD activity to 50 percent of normal in all tissues from birth, and homozygous or heterozygous disease variants in<em> HFE</em> (the hereditary hemochromatosis gene), which increase iron absorption. (See  <a class="medical medical_review" href="/z/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HEP</strong> – HEP is caused by severely deficient UROD activity on a genetic basis due to pathogenic variants affecting both <em>UROD</em> alleles (one from each parent). Only approximately 40 cases of HEP have been documented worldwide.</p><p></p><p>PCT can be classified as "sporadic" or "familial" based on the absence or presence of a pathogenic variant in <em>UROD</em>. Familial cases may present at an earlier age, but in these cases the family history is often negative for PCT. Finding a <em>UROD</em> disease variant warrants genetic counseling. (See  <a class="medical medical_review" href="/z/d/html/101414.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis", section on 'Asymptomatic UROD variants'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCT type 1 (sporadic)</strong> – Absence of a <em>UROD</em> disease variant; accounts for approximately 80 percent of individuals with PCT [<a href="#rid4">4,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCT type 2 (familial)</strong> – Inheritance of a <em>UROD</em> disease variant at one allele (heterozygous); present in approximately 20 percent of individuals with PCT. Inheritance is autosomal dominant with low penetrance, so there are often no relatives with PCT. Other factors must be present to reduce hepatic UROD activity from 50 percent of normal (due to the gene variant) to &lt;20 percent of normal and cause significant porphyrin accumulation, initially in the liver, and the clinical features that follow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCT type 3 (familial)</strong> – Apparent familial inheritance without a pathogenic variant in <em>UROD</em>; may be due to other inherited factors such as an <em>HFE</em> variant or to shared acquired factors.</p><p></p><p>The great majority of individuals who are heterozygous for a <em>UROD</em> disease variant do not manifest clinical findings of PCT. Some may have subclinical elevations of plasma and urinary porphyrins.</p><p class="headingAnchor" id="H2865927"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>PCT is caused by deficient activity of the fifth enzyme in the heme synthetic pathway, uroporphyrinogen decarboxylase (UROD), which is caused by acquired inhibition of hepatic UROD, with a heterozygous pathogenic variant in the <em>UROD</em> gene sometimes contributing (<a class="graphic graphic_figure graphicRef117995" href="/z/d/graphic/117995.html" rel="external">figure 1</a>). Hepatoerythropoietic porphyria (HEP) is an extremely rare condition caused by homozygosity or compound heterozygosity for pathogenic variants in <em>UROD</em>.</p><p>UROD is a cytosolic enzyme that catalyzes the four-step decarboxylation of uroporphyrinogen to coproporphyrinogen, which have eight and four carboxyl groups, respectively [<a href="#rid6">6,7</a>]. In the enzymatic reaction the four carboxyl groups are removed sequentially in a clockwise fashion starting from ring D. The enzyme has greater affinity for uroporphyrinogen III than uroporphyrinogen I.</p><p class="headingAnchor" id="H1422429236"><span class="h2">Reduced hepatic UROD activity and porphyrin accumulation</span><span class="headingEndMark"> — </span>Reduced hepatic UROD activity is responsible for the accumulation of porphyrinogens that are auto-oxidized to photosensitizing porphyrins in PCT. Reduction of UROD activity in the liver to &lt;20 percent of normal is required for clinical manifestations of PCT to occur.</p><p>Reduced hepatic UROD activity leads to accumulation of highly carboxylated porphyrinogens; these are oxidized to the corresponding porphyrins (mostly uroporphyrin and heptacarboxyl porphyrins), which appear in plasma and are excreted mostly in urine [<a href="#rid8">8,9</a>]. Excess porphyrins consist of both I and III isomers, resulting in a complex, characteristic pattern (<a class="graphic graphic_table graphicRef60572" href="/z/d/graphic/60572.html" rel="external">table 1</a>). </p><p>Pentacarboxyl porphyrinogen that accumulates can be further metabolized by the next enzyme in the heme biosynthetic pathway (coproporphyrinogen oxidase) to dehydro-isocoproporphyrinogen, an atypical tetracarboxyl porphyrinogen. After oxidation, this appears in feces and urine in the form of isocoproporphyrins, with additional modifications by intestinal bacteria. Excess porphyrins are transported from the liver to skin in PCT, leading to cutaneous phototoxicity. (See <a class="local">'Photosensitization'</a> below.)</p><p>PCT does not appear to be associated with marked upregulation of delta-aminolevulinic acid (ALA) synthase (ALAS1), the first and rate-limiting enzyme in the heme biosynthetic pathway; this contrasts with acute intermittent porphyria (AIP), in which marked upregulation of ALAS1 is common.</p><p>Little elevation of hepatic ALAS1 is needed to account for the amounts of excess porphyrins excreted in PCT. Accordingly, factors that increase ALAS1 synthesis, including a variety of drugs, hormones, caloric restriction, and metabolic stress, seldom appear to play a significant role in the pathogenesis of PCT. The major environmental/behavioral susceptibility factors in PCT impair UROD activity by promoting iron accumulation or oxidative stress in hepatocytes rather than by inducing ALAS1.</p><p class="headingAnchor" id="H1422430102"><span class="h2">Photosensitization</span><span class="headingEndMark"> — </span>Porphyrins that accumulate in PCT are photosensitizing; they are transported to the skin and cause phototoxic damage on exposure to light with a wavelength near 400 nm (ie, wavelengths within the ultraviolet A and visible light ranges (<a class="graphic graphic_figure graphicRef70045" href="/z/d/graphic/70045.html" rel="external">figure 2</a>)). These wavelengths of light cause porphyrins to enter an excited state and release photons that activate oxygen in tissues to higher energy singlet oxygen, which damages proteins, lipids, and basement membranes [<a href="#rid10">10,11</a>]. This results in dermoepidermal separation and blister formation [<a href="#rid12">12</a>]. Activation of complement, degranulation of mast cells, and increases in levels of transforming growth factor (TGF)-beta may also play a role [<a href="#rid11">11,13</a>].</p><p class="headingAnchor" id="H1422430178"><span class="h2">Significance of pathogenic variants in the <i>UROD </i>gene</span><span class="headingEndMark"> — </span>Unlike other porphyrias, a pathogenic variant in the gene that encodes the relevant enzyme is not required to cause PCT. Rather, acquired and/or other genetic factors are important in causing reduced hepatic UROD activity in patients with or without heterozygosity for a <em>UROD</em> disease variant [<a href="#rid4">4</a>]. (See <a class="local">'UROD inhibitor'</a> below and <a class="local">'HFE'</a> below.)</p><p>Inherited variants in the <em>UROD</em> gene (OMIM #176100, OMIM #176090) are seen in approximately 20 percent of individuals with PCT who are classified as having type 2 familial PCT [<a href="#rid4">4,5</a>]. A pathogenic variant affects one <em>UROD</em> allele in PCT, whereas biallelic <em>UROD</em> pathogenic variants cause HEP [<a href="#rid8">8,9,14,15</a>]. Over 100 <em>UROD</em> pathogenic variants have been described in PCT and HEP, many of which are cataloged in the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.hgmd.cf.ac.uk%2Fac%2Findex.php&amp;token=w7p0LC3%2F%2Bc5TTfDIkVSPKuXOHlNonGDNq2foBOcxWHjS2ipCxB5EMN1sOeOrxH2h&amp;TOPIC_ID=7108" target="_blank">human genome mutation database</a>. These include missense and nonsense mutations, deletions, and insertions [<a href="#rid16">16-21</a>].</p><p>Despite the central role of deficient hepatic UROD activity in PCT, most patients with heterozygous <em>UROD</em> pathogenic variants will not develop symptomatic disease. This is because a single <em>UROD</em> pathogenic variant only reduces UROD activity to approximately 50 percent of normal, whereas reduction of the hepatic enzyme activity to &lt;20 percent of normal is required for disease manifestations to occur. However, some heterozygous individuals have elevated porphyrins in the absence of skin manifestations; it is not known how frequently this occurs. (See  <a class="medical medical_review" href="/z/d/html/101414.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis", section on 'Asymptomatic UROD variants'</a>.)</p><p>More severe reductions of UROD activity occur when both <em>UROD</em> alleles have a pathogenic variant, resulting in HEP [<a href="#rid3">3</a>]. This leads to marked increases in highly carboxylated porphyrins in liver, plasma, urine, and feces, and (in contrast with PCT) marked increase in erythrocyte zinc protoporphyrin. The increase in zinc protoporphyrin in HEP is thought to result from the accumulation of heme pathway intermediates during hemoglobin synthesis, which are metabolized to protoporphyrin and then complexed with zinc after hemoglobin synthesis is complete [<a href="#rid3">3</a>]. At least one of the <em>UROD</em> pathogenic variants in HEP must permit expression of some UROD enzymatic activity, as homozygosity for complete loss of function variants is presumed to be lethal [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H1422430768"><span class="h2">Central importance of iron in PCT</span><span class="headingEndMark"> — </span>Increased hepatic iron plays a central role in the pathogenesis of PCT, as illustrated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased hepatic iron deposition (siderosis) is found in the great majority of patients with PCT who undergo liver biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeated phlebotomy to reduce hepatic iron content is an effective and widely accepted treatment for PCT [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/101414.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis", section on 'Phlebotomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iron deficiency is protective in humans as well as animal models of PCT [<a href="#rid23">23,24</a>].</p><p></p><p>A common cause of iron accumulation in PCT may be reduced production of hepcidin by the liver, which has been demonstrated in PCT even in the absence of <em>HFE </em>mutations, and consequently, there is failure to appropriately downregulate iron absorption [<a href="#rid25">25,26</a>]. </p><p>Iron may contribute to the pathogenesis of PCT by facilitating the formation of oxygen free radicals and thereby contributing to the oxidative formation of a UROD inhibitor (see <a class="local">'UROD inhibitor'</a> below) [<a href="#rid22">22</a>]. However, hepatic hemosiderosis alone is insufficient to cause PCT, as illustrated by the observations that the majority of individuals with hereditary hemochromatosis or transfusional iron overload do not develop PCT, and hepcidin gene deletion in mice does not produce a PCT syndrome.</p><p class="headingAnchor" id="H88983403"><span class="h2">UROD inhibitor</span><span class="headingEndMark"> — </span>Acquired susceptibility factors for PCT are thought to lead to generation of a UROD inhibitor in the liver. Most of the environmental/behavioral susceptibility factors promote iron accumulation or oxidative stress in hepatocytes. (See <a class="local">'Significance of pathogenic variants in the UROD gene'</a> above.)</p><p>In studies in a mouse model of PCT, a UROD inhibitor was isolated as a uroporphomethene, a partially oxidized uroporphyrinogen molecule. Generation of the inhibitor from uroporphyrinogen I or III may be catalyzed by the cytochrome P450 (CYP) isoform CYP1A2, in the presence of increased hepatic iron (<a class="graphic graphic_figure graphicRef67596" href="/z/d/graphic/67596.html" rel="external">figure 3</a>) [<a href="#rid22">22</a>]. However, iron itself is not considered to directly inhibit hepatic UROD.</p><p>In contrast with PCT, the hepatic UROD inhibitor is not thought to play a significant role in the pathogenesis of HEP, because UROD activity in these patients is already &lt;20 percent of normal due to biallelic pathogenic variants in <em>UROD</em>. (See <a class="local">'Significance of pathogenic variants in the UROD gene'</a> above.)</p><p class="headingAnchor" id="H1422430915"><span class="h2">Susceptibility factors</span><span class="headingEndMark"> — </span>Some factors that increase susceptibility to PCT can damage the liver, such as alcohol use or HCV infection, as can PCT itself. These and other susceptibility factors are quite specific for PCT and distinct from those for other porphyrias. However, some of the susceptibility factors for PCT, such as HIV infection, are unlikely to be hepatotoxic, and hepatic injury in general does not lead to development of PCT. In one series, most patients with PCT had multiple susceptibility factors, with three or more susceptibility factors identified in at least 70 percent of 143 patients [<a href="#rid4">4</a>].</p><p>Susceptibility factors are less likely to play a role in HEP because individuals with HEP have markedly reduced UROD activity in the absence of such factors.</p><p>Most of the susceptibility factors for PCT either decrease hepcidin expression (thereby increasing iron absorption), increase oxidative stress in hepatocytes (favoring the production of the UROD inhibitor), or both. As described in the following sections, susceptibility is unexplained for some of these factors. <em>UROD</em> pathogenic variants act as susceptibility factors by decreasing the amount of the enzyme in liver (and all tissues) from birth. Various combinations of these acquired and inherited factors are found in different patients.</p><p>Addressing relevant susceptibility factors is an important component of PCT management. (See  <a class="medical medical_review" href="/z/d/html/101414.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis", section on 'Counseling regarding susceptibility factors'</a>.)</p><p class="headingAnchor" id="H43991160"><span class="h3">Alcohol</span><span class="headingEndMark"> — </span>Use of alcohol has been reported as an important and common susceptibility factor for PCT in many series [<a href="#rid4">4,27-29</a>]. In a series of 131 individuals with PCT, 115 (88 percent) reported alcohol use [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1">However, PCT remains rare in individuals with alcoholic liver disease. In one report of 360 patients with alcoholic cirrhosis followed for 10 years, only 2 percent had PCT [<a href="#rid30">30</a>]. Therefore, alcohol is never the sole cause of PCT. Alcohol may contribute to the pathogenesis of PCT by a variety of mechanisms including increased oxidative stress and downregulation of hepcidin [<a href="#rid31">31,32</a>].</p><p></p><p class="headingAnchor" id="H43991180"><span class="h3">HCV infection</span><span class="headingEndMark"> — </span>Infection with hepatitis C virus (HCV) is strongly implicated in the pathogenesis of PCT. A systematic review and meta-analysis that included 50 studies (2167 patients with PCT) found an overall prevalence of HCV of 50 percent [<a href="#rid33">33</a>]. From eight case-control studies included in the meta-analysis, the odds of HCV infection in patients with PCT was 275:1 (95% CI 104-725). Geographic variability paralleled the baseline rates of HCV infection in the associated general population, with lowest prevalence rates observed in reports from Australia, the Czech Republic, and France (20 to 30 percent), and higher rates in Japan, Italy, and Spain (71 to 85 percent). The prevalence in North America was 66 percent. </p><p></p><p class="bulletIndent1">PCT is estimated to occur in approximately 0.5 percent of HCV-infected individuals and is among the extrahepatic manifestations that add to the disease burden and costs of HCV infection [<a href="#rid34">34</a>].</p><p></p><p>The exact mechanism by which HCV infection increases PCT risk is unknown [<a href="#rid35">35</a>]. Several potential mechanisms have been proposed, including the ability of HCV to decompartmentalize iron from within the hepatocyte, leading to the release of free iron that in turn leads to production of a UROD inhibitor by an oxidative process [<a href="#rid36">36,37</a>]. Most importantly, HCV increases oxidative stress in hepatocytes and increases iron absorption by dysregulating hepcidin [<a href="#rid38">38,39</a>]. Regardless of mechanism, evidence now shows that successful treatment of HCV infection can lead to resolution of PCT [<a href="#rid40">40,41</a>].</p><p class="headingAnchor" id="H43991218"><span class="h3">HIV infection</span><span class="headingEndMark"> — </span>PCT can occur early or late in the course of HIV infection [<a href="#rid42">42-45</a>]. A mechanism whereby HIV infection might contribute to development of PCT has not been established; HIV is often associated with concomitant HCV infection or other susceptibility factors. In a series involving seven people with PCT and HIV in the United States, HCV co-infection was present in three and absent in four [<a href="#rid4">4</a>]. In contrast, in a series involving 26 people with PCT and HIV in Spain, all but one had HCV co-infection [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1422431365"><span class="h3">Estrogen exposure</span><span class="headingEndMark"> — </span>Use of exogenous estrogens has been identified as a susceptibility factor for PCT, including estrogens in oral contraceptives, menopausal hormone therapy, and (in the past) therapy for prostate cancer [<a href="#rid27">27-29,47-50</a>]. Estrogen use was reported in 31 of 47 females with PCT in one series (66 percent) [<a href="#rid4">4</a>]. </p><p></p><p>The mechanism by which estrogens increase susceptibility to PCT is unclear. Estrogens undergo redox cycling and cause oxidative damage in the kidney of rodents, but this has not been demonstrated in the liver [<a href="#rid51">51</a>]. Estrogens are not potent inducers of ALAS1, in contrast with progesterone and progestins, which are often implicated in exacerbating the acute hepatic porphyrias.</p><p class="headingAnchor" id="H1422431766"><span class="h3">Smoking</span><span class="headingEndMark"> — </span>Cigarette smoke containing polycyclic aromatic hydrocarbons may contribute to the pathogenesis of PCT by inducing CYP1A2 synthesis, leading to increased production of the UROD inhibitor [<a href="#rid22">22</a>]. (See <a class="local">'UROD inhibitor'</a> above.)</p><p>In a large series, 81 percent of patients with PCT were smokers, and in a group of patients with PCT who did not have pathogenic variants in <em>UROD</em>, disease onset was earlier among smokers than nonsmokers [<a href="#rid4">4,52</a>]. A genetic polymorphism that favors greater inducibility of CYP1A2 was also found more commonly in individuals with PCT than in age-matched controls in the community [<a href="#rid53">53,54</a>]. This CYP1A2 gene variation may represent an additional PCT susceptibility factor.</p><p class="headingAnchor" id="H1422431028"><span class="h3"><i>HFE</i></span><span class="headingEndMark"> — </span><em>HFE</em> is the hereditary hemochromatosis (HH) gene; the C282Y variant in HFE increases the risk of iron overload. (See  <a class="medical medical_review" href="/z/d/html/7067.html" rel="external">"<i>HFE</i> and other hemochromatosis genes"</a>.)</p><p><em>HFE</em> encodes a component of a complex on the surface membrane of hepatocytes that senses the level of iron in plasma and regulates hepatic expression of the hormone hepcidin. Hepcidin reduces iron absorption from the gut by downregulating ferroportin, the iron transporter found on the basolateral membrane of enterocytes. Iron absorption remains inappropriately high in HH, even with high iron levels in the circulation, because liver expression of hepcidin is inappropriately low.</p><p>Increased prevalence of<em> HFE</em> C282Y in individuals with PCT has been reported in many studies, even in the absence of overt HH [<a href="#rid29">29,55,56</a>]. A study that compared <em>HFE </em>genotypes in individuals with PCT versus controls without PCT found homozygosity for <em>HFE </em>C282Y in 17 of 87 patients with PCT (19 percent), versus 0 percent of controls; compound heterozygosity for C282Y and H63D was found in six patients with PCT (7 percent) versus 0 percent of controls [<a href="#rid55">55</a>]. Heterozygosity for C282Y or H63D alone, which would have less effect on iron absorption, is increased in some studies but not others.</p><p>The increased likelihood of PCT in individuals with <em>HFE </em>variants was further demonstrated in a meta-analysis that evaluated the risk of various diseases in patients according to <em>HFE</em> genotype [<a href="#rid57">57</a>]. This found greatly increased likelihood of PCT in individuals with C282Y/C282Y and C282Y/H63D genotypes (odds ratios [ORs], 48 and 8, respectively).</p><p>Variants in other genes that modify iron absorption may also play a role in PCT. As an example, the (D519G) variant in the gene for glyceronephosphate O-acyltransferase (<em>GNPAT</em>) was found by exome sequencing to be associated with a particularly high-iron phenotype in individuals who were homozygous for <em>HFE</em> C282Y and to decrease hepcidin expression [<a href="#rid58">58</a>]. A study in 240 patients with PCT found an increased prevalence of this <em>GNPAT</em> variant particularly in patients with <em>UROD</em> pathogenic variants [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H43991298"><span class="h3">Other medical conditions</span><span class="headingEndMark"> — </span>Medical conditions that can cause oxidative liver damage have been prevalent in some PCT series; these include diabetes mellitus and hepatic steatosis [<a href="#rid27">27,60</a>]. </p><p>PCT also has been reported in late pregnancy; however, an increased prevalence during pregnancy or a causal relationship was not identified [<a href="#rid47">47</a>]. </p><p>PCT has been reported in patients with myeloproliferative disorders, usually in association with substantial iron overload [<a href="#rid61">61</a>]. </p><p>PCT may occur in patients undergoing hemodialysis or peritoneal dialysis for advanced chronic kidney disease, often with associated iron overload [<a href="#rid62">62,63</a>]. The disease is often especially severe in such cases, reflecting plasma porphyrin levels that may be much higher than in patients with PCT and normal kidney function.</p><p class="headingAnchor" id="H43991314"><span class="h3">Halogenated hydrocarbons</span><span class="headingEndMark"> — </span>In the 1950s, PCT developed in thousands of adults and children in eastern Turkey who were exposed to hexachlorobenzene, a fungicide used to treat seed wheat, which was consumed during a famine [<a href="#rid64">64,65</a>]. </p><p>Subsequently, it was shown that hexachlorobenzene and other halogenated hydrocarbons can cause deficient hepatic UROD activity and increased porphyrins in laboratory animals, with porphyrin patterns resembling those seen in PCT. </p><p>Smaller outbreaks have been associated with industrial exposure to tetrachlorodibenzo-p-dioxin (TCDD) [<a href="#rid66">66</a>]. </p><p>Sporadic cases attributed to exposure to other chemicals, such as <a class="drug drug_general" data-topicid="9562" href="/z/d/drug information/9562.html" rel="external">lindane</a> and diazinon, are of uncertain significance [<a href="#rid67">67,68</a>]. Such chemical exposures are rarely recognized as contributing to PCT in clinical practice.</p><p class="headingAnchor" id="H2865988"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>PCT is reported worldwide. The prevalence of symptomatic disease has been estimated to be 1 in 5000 in Czechoslovakia and 1 in 25,000 in the United States [<a href="#rid69">69</a>]. A series from the Norwegian Porphyria Centre (NAPOS) estimated a prevalence of 1 in 10,000 [<a href="#rid70">70</a>].</p><p>PCT is generally a disease of adults; it usually presents in mid or late life. Earlier onset is noted in some patients with pathogenic variants in <em>UROD </em>or <em>HFE</em> [<a href="#rid71">71</a>].</p><p>In contrast, HEP, caused by biallelic pathogenic variants in <em>UROD</em>, is extremely rare, with only approximately 40 cases documented. Disease onset is in childhood, usually &lt;2 years of age, although onset in adulthood has been reported [<a href="#rid19">19,72</a>].</p><p>Females and males are probably equally susceptible to PCT and HEP. Certain risk factors for PCT such as alcohol use, smoking, and hepatitis C virus (HCV) infection, may be more common in males, whereas estrogen use is more common in females.</p><p>PCT is more common in individuals with <em>HFE </em>variants, and especially C282Y, even in the absence of hemochromatosis, and in individuals with alcoholic liver disease, HCV infection, smoking, and exogenous estrogen use. (See <a class="local">'Susceptibility factors'</a> above.)</p><p class="headingAnchor" id="H2866211"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>PCT is characterized by chronic blistering skin lesions and is often accompanied by elevated hepatic transaminases. Hepatic manifestations may be related to marked accumulation of porphyrins in hepatocytes and in part to manifestations of susceptibility factors. (See <a class="local">'Susceptibility factors'</a> above.)</p><p>Sporadic (type 1) and familial (types 2 and 3) PCT are clinically indistinguishable, but their differentiation (based on <em>UROD</em> genetic testing) and identification of other susceptibility factors for PCT may affect management. </p><p>Examples include increased importance of phlebotomy for individuals with <em>HFE</em> variants such as C282Y and initial treatment for hepatitis C virus (HCV) infection. There may also be implications for genetic counseling. (See  <a class="medical medical_review" href="/z/d/html/101414.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis", section on 'Asymptomatic UROD variants'</a>.)</p><p class="headingAnchor" id="H2866233"><span class="h2">Blistering skin lesions and other cutaneous manifestations</span><span class="headingEndMark"> — </span>Characteristic cutaneous manifestations of PCT include [<a href="#rid8">8,9,27,73-75</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic photosensitivity with bullae (blisters)</p><p class="bulletIndent1"><span class="glyph">●</span>Increased skin fragility</p><p class="bulletIndent1"><span class="glyph">●</span>Scarring</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperpigmentation and hypopigmentation affecting sun-exposed areas of the body </p><p class="bulletIndent1"><span class="glyph">●</span>Itching, which may be especially troublesome for some individuals</p><p class="bulletIndent1"><span class="glyph">●</span>Hirsutism, especially on the cheeks and forearms</p><p class="bulletIndent1"><span class="glyph">●</span>Alopecia</p><p></p><p>The backs of the hands, forearms, face, ears, neck, and feet are most commonly affected (<a class="graphic graphic_picture graphicRef74528 graphicRef78547 graphicRef56810" href="/z/d/graphic/74528.html" rel="external">picture 1A-C</a>). </p><p>The reaction to sun exposure is delayed rather than immediate, and as a result patients may not be aware that such exposure is the problem. This contrasts markedly with the acute mostly nonblistering photosensitivity experienced in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). (See  <a class="medical medical_review" href="/z/d/html/7125.html" rel="external">"Erythropoietic protoporphyria and X-linked protoporphyria"</a>.)</p><p>Increased mechanical fragility of skin leads to blistering or superficial erosions from trivial trauma [<a href="#rid8">8</a>]. Bullae contain serous or serosanguinous fluid and are not inflamed. Skin lesions may be painful and may become infected [<a href="#rid27">27</a>]. </p><p>Scarring in some patients may progress to "pseudoscleroderma" with contraction and calcification resembling the cutaneous findings in scleroderma [<a href="#rid27">27,76</a>]. </p><p>The burden and severity of symptoms, as well as delays in treatment, impact health-related quality of life in PCT [<a href="#rid77">77</a>]. </p><p>Cutaneous findings in HEP are similar to those in PCT, except they may be more severe and they often first develop during childhood. </p><p>Some cases of PCT with greater than usual elevations of plasma porphyrins due to chronic kidney disease may present with more severe symptoms resembling congenital erythropoietic porphyria (CEP), with bacterial superinfection, hypertrichosis, and severe/disfiguring scarring. (See  <a class="medical medical_review" href="/z/d/html/7102.html" rel="external">"Congenital erythropoietic porphyria", section on 'Cutaneous'</a>.)</p><p class="headingAnchor" id="H2866476"><span class="h2">Hepatic involvement</span><span class="headingEndMark"> — </span>Hepatic abnormalities are seen in most cases of PCT, probably due to marked porphyrin accumulation in hepatocytes. </p><p>Hepatic injury can result in part from the associated susceptibility factors such as alcohol, HCV infection, or iron overload. Advanced liver disease is uncommon at initial presentation but may be seen in older patients with recurrent disease [<a href="#rid27">27,29</a>]. Patients with PCT have an increased long-term risk for cirrhosis and hepatocellular carcinoma [<a href="#rid27">27,78-80</a>]. This risk can persist after treatment but has been little studied.</p><p>Liver biopsy is not required for diagnosis of PCT or HEP. However, massive porphyrin accumulation in the liver is characteristic and can be demonstrated by biochemical measurement of the accumulated porphyrins in liver tissue (mostly uroporphyrin and heptacarboxyl porphyrin), and by reddish fluorescence on illumination of fresh liver tissue using a Wood's lamp (a UVA light source) or fluorescence microscopy. </p><p>The red fluorescence does not intensify on oxidation, suggesting that the accumulated porphyrins are in their oxidized form and are not porphyrinogens. Microscopy after fixation shows these as needle-shaped crystals within hepatocytes [<a href="#rid81">81</a>]. However, fixation may alter the intracellular distribution of the accumulated porphyrins. </p><p>Nonspecific histopathologic findings may include varying degrees of siderosis, steatosis, portal triaditis, focal lobular necrosis, and periportal fibrosis [<a href="#rid27">27,78,82</a>].</p><p>In HEP, mild and nonspecific abnormalities in liver function and histology are common, usually without siderosis. Hepatosplenomegaly may be seen and be associated with hemolytic anemia.</p><p class="headingAnchor" id="H2866678"><span class="h2">Laboratory abnormalities</span><span class="headingEndMark"> — </span>The major laboratory abnormalities in PCT are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased porphyrins</strong> – Plasma and urinary porphyrins are increased, with a characteristic pattern of highly carboxylated porphyrins; many patients also have increases in hepatic transaminases [<a href="#rid26">26,83-88</a>]. (See <a class="local">'Laboratory testing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematologic changes</strong> – Generally, the complete blood count (CBC) is normal in PCT. The hemoglobin is sometimes elevated, possibly related to smoking and chronic lung disease. Anemia is uncommon and if present is due to a concurrent condition other than iron deficiency, which is protective. </p><p></p><p class="bulletIndent1">Serum ferritin levels are usually normal or modestly increased. Substantially increased ferritin levels suggest concurrent hemochromatosis or the effects of an inflammatory condition.</p><p></p><p class="bulletIndent1">In HEP, hematologic abnormalities may include mild normocytic, normochromic anemia, due in part to hemolysis [<a href="#rid8">8</a>]. Severe anemia has been reported but is unusual in HEP [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic transaminase elevations</strong> – PCT is almost always associated with mild elevations in liver enzymes, with alanine aminotransferase (ALT) usually exceeding aspartate aminotransferase (AST). These elevations may be due to effects of large amounts of porphyrins in hepatocytes as well as hepatotoxic effects of iron, alcohol, and/or HCV infection. (See <a class="local">'Hepatic involvement'</a> above.)</p><p></p><p class="bulletIndent1">However, PCT is not known to present with isolated transaminase elevations. Other causes of abnormal liver function tests should be excluded. (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>UROD activity and genotype</strong> – Erythrocyte UROD activity will be normal in individuals with sporadic (type 1) PCT, and approximately half-normal in individuals with familial (type 2) PCT. In HEP, erythrocyte UROD activity will be markedly reduced (typically &lt;20 percent of normal). Because UROD activity is higher in younger erythrocytes and declines as these cells age in the circulation, increased erythropoiesis may cause an increase in measured erythrocyte UROD activity [<a href="#rid89">89</a>]. Therefore, deficient UROD activity may not be detected in erythrocytes of type 2 patients with increased erythropoiesis (eg, due to recent phlebotomies).</p><p></p><p class="bulletIndent1">Genetic testing of <em>UROD</em> will not show a pathogenic variant in the majority of patients with PCT. Those with familial disease typically will have heterozygosity for a pathogenic variant in <em>UROD</em> (approximately 20 percent of individuals with PCT), and those with HEP will have biallelic pathogenic variants in <em>UROD</em> [<a href="#rid14">14,15,90</a>]. (See <a class="local">'Significance of pathogenic variants in the UROD gene'</a> above.)</p><p></p><p class="headingAnchor" id="H2866979"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>PCT should be suspected in an adult (or rarely, a child) who presents with blistering lesions on sun-exposed skin, without neurovisceral symptoms such as attacks of unexplained abdominal pain; pain in the chest, back, or extremities; or neurologic symptoms including numbness, weakness, autonomic changes, or seizures (<a class="graphic graphic_algorithm graphicRef89035" href="/z/d/graphic/89035.html" rel="external">algorithm 1</a>). HEP may be suspected in a child or adult who presents with these symptoms, which are usually more severe than in PCT.</p><p>As with other porphyrias, the preferred approach to the evaluation is to perform a single first-line test for screening, followed by more extensive testing to differentiate PCT from other blistering cutaneous porphyrias if the screening test is positive. (See <a class="local">'Laboratory testing'</a> below.)</p><p>Evaluation for other causes of blistering skin lesions is pursued if the screening test is negative. Biopsies (skin, liver, bone marrow) are not necessary for diagnosing PCT, although they may be performed to evaluate the possibility of blistering skin diseases other than porphyria.</p><p>Once a diagnosis of PCT is made, patients should be evaluated for acquired and inherited susceptibility factors, including testing for pathogenic variants in <em>UROD</em> and <em>HFE</em>. If clinically important variants are found, testing can be extended to other family members; this subject is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/101414.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis", section on 'Asymptomatic UROD variants'</a>.)</p><p class="headingAnchor" id="H138282"><span class="h2">Patient and family history</span><span class="headingEndMark"> — </span>The patient history can be helpful for identifying a typical pattern of chronic blistering lesions on sun-exposed skin and absence of neurovisceral manifestations. The patient history is also important for identifying susceptibility factors that have an etiologic role in disease activity for that patient. Attention should be paid to alcohol intake, smoking, estrogen use, known HCV and HIV infection, and unusual chemical exposures.</p><p>Individuals with PCT or HEP usually have a negative family history for PCT, and the absence of a family history of porphyria does not reduce the likelihood of PCT, because most cases of PCT are sporadic and inherited susceptibility factors have low penetrance. However, the family history may reveal relatives with PCT or skin blistering and suggest shared susceptibility factors such as variants in <em>UROD</em> or <em>HFE</em>.</p><p class="headingAnchor" id="H2867283"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Measurement of total porphyrins in plasma (or serum) is the preferred first step in the laboratory evaluation for suspected PCT (or HEP) (<a class="graphic graphic_algorithm graphicRef89035" href="/z/d/graphic/89035.html" rel="external">algorithm 1</a>). Measurement of total urine porphyrins on a spot urine sample can also be used, with the caveat that urine porphyrins are more often nonspecifically elevated in other medical conditions. </p><p>A 24-hour urine collection is not required. Measuring creatinine in the same urine sample is recommended so results can be expressed per gram (or micromole) of creatinine.</p><p>Porphyrins are chronically elevated in the urine and plasma in patients with PCT and HEP (<a class="graphic graphic_table graphicRef60572" href="/z/d/graphic/60572.html" rel="external">table 1</a>), even though blistering may be absent or appear intermittently, such as in response to minor trauma to the backs of the hands. Laboratory testing may detect porphyrin elevations even if skin lesions are absent at the time of testing. Some patients have reduced erythrocyte uroporphyrinogen decarboxylase activity, indicating the presence of a heterozygous <em>UROD</em> gene mutation.</p><p>Testing is summarized in the table (<a class="graphic graphic_table graphicRef89036" href="/z/d/graphic/89036.html" rel="external">table 2</a>) [<a href="#rid91">91</a>]. The laboratory evaluation begins with a first-line test, which, if negative, excludes PCT and other blistering porphyrias; in this case, no further testing is required. If the first-line test is abnormal, this is followed by more comprehensive second-line testing to document either PCT, another blistering cutaneous porphyria, or a nonspecific porphyrin elevation due to a non-porphyria condition.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-line testing with measurement of total porphyrins in either plasma or urine</strong> – Urine or plasma total porphyrins, which are both elevated in PCT, HEP, and other blistering cutaneous porphyrias, should be measured as first-line tests whenever these porphyrias are suspected. </p><p></p><p class="bulletIndent1">Urine porphyrin results should be normalized to creatinine concentration if a spot (random) sample is obtained. </p><p></p><p class="bulletIndent1">Plasma and urine samples should be protected from light during processing and transit because porphyrins are light sensitive. However, substantially elevated porphyrin levels are very unlikely to be reduced to normal by even lengthy light exposure.</p><p></p><p class="bulletIndent1">Normal total urine or plasma porphyrins exclude all porphyrias that cause blistering skin lesions, even if slight increases in some individual porphyrins are found [<a href="#rid92">92</a>]; in such cases, evaluation should focus on other bullous (blistering) skin diseases (see <a class="local">'Differential diagnosis'</a> below), with early input from the consulting dermatologist. However, erythropoietic protoporphyria (EPP), which causes nonblistering photosensitivity, is excluded only if erythrocyte protoporphyrin is measured by a reliable laboratory. (See  <a class="medical medical_review" href="/z/d/html/7125.html" rel="external">"Erythropoietic protoporphyria and X-linked protoporphyria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-line testing</strong> – Elevation of total porphyrins, especially in urine, is a <strong>nonspecific finding</strong>,<em> </em>and further second-line testing, including porphyrin fractionation, is needed for documenting a diagnosis of porphyria as a cause of blistering skin lesions. </p><p></p><p class="bulletIndent1">Although PCT is by far the most common type of porphyria to cause skin blistering, other less common porphyrias (including HEP) should be excluded. Other diagnostic possibilities include variegate porphyria (VP), hereditary coproporphyria (HCP), congenital erythropoietic porphyria (CEP), autosomal dominant forms of acute hepatic porphyrias, and harderoporphyria. VP and HCP, like PCT, usually present in adulthood. Although the others usually become manifest in childhood, rare adult-onset cases are reported and are often misdiagnosed as PCT. Treatment for PCT is specific to PCT and should not begin until these other blistering cutaneous porphyrias are excluded. This evaluation involves the following testing:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fractionation of urine and/or plasma porphyrins</strong> – It is essential to demonstrate a predominance of highly carboxylated porphyrins (uroporphyrin, hepta-, hexa-, and pentacarboxyl porphyrins) rather than coproporphyrin, in order to make a diagnosis of PCT or HEP. These porphyrins are water soluble and therefore mostly excreted in urine. In HEP, the pattern of porphyrin elevations in urine and plasma closely resembles that seen in PCT, but HEP is distinguished especially by a marked elevation in erythrocyte protoporphyrin (mostly zinc protoporphyrin) [<a href="#rid90">90,93-95</a>]. A predominance of highly carboxylated porphyrins in urine is not completely specific for PCT. This pattern of urinary porphyrins has been reported, for example, in some patients with VP [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Determination of the plasma fluorescence peak wavelength at neutral pH (pH 7.4)</strong> – Patients with elevated total plasma porphyrins should also have determination of the plasma fluorescence peak (diluted at neutral pH). PCT and HEP are characterized by peak plasma fluorescence at approximately 620 nm (following excitation at approximately 410 nm, the Soret band); in contrast, a peak at approximately 626 nm is diagnostic for VP. Therefore, this test is especially useful for early differentiation of VP, which is often initially misdiagnosed (and mistakenly treated) as PCT.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Measurement of erythrocyte total porphyrins, with fractionation if elevated</strong> – Patients with elevated plasma or urine porphyrins should have erythrocyte (red blood cell) porphyrins measured. Erythrocyte total porphyrins are normal or only mildly elevated in PCT. The purpose of this testing is to exclude HEP, autosomal dominant forms of acute hepatic porphyrias, and harderoporphyria (in which erythrocyte zinc protoporphyrin is substantially increased); and to exclude mild, adult-onset cases of congenital erythropoietic porphyria (CEP, in which uroporphyrin I, coproporphyrin I, and zinc protoporphyrin are increased).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Measurement of urinary delta-aminolevulinic acid (ALA) and porphobilinogen (PBG)</strong> – Urinary ALA is usually normal in PCT and HEP but may be mildly elevated; urinary PBG is normal. These findings provide for additional exclusion of HCP and VP.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Measurement of fecal total porphyrins, with fractionation if elevated</strong> – Fecal total porphyrins are usually normal or modestly elevated in PCT and are expected to be more substantially elevated in HEP and other blistering porphyrias. Porphyrin fractionation by high-performance liquid chromatography (HPLC) is likely to show a complex pattern in PCT and HEP including isocoproporphyrins as well as some of the highly carboxylated porphyrins that are excreted mostly in urine. These findings provide additional confirmation and distinction from CEP, in which markedly elevated fecal porphyrins are predominantly coproporphyrin I. Marked elevation of fecal porphyrins is also found in HCP and VP and in autosomal dominant forms of acute hepatic porphyrias and harderoporphyria [<a href="#rid8">8,86</a>].</p><p></p><p class="bulletIndent1">Measurement of plasma porphyrin levels (along with serum ferritin in individuals with iron overload) in monitoring disease and response to therapy is presented separately. (See  <a class="medical medical_review" href="/z/d/html/101414.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis", section on 'Monitoring with hydroxychloroquine'</a>.)</p><p></p><p class="headingAnchor" id="H3778891849"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>Skin biopsy is not required for the diagnosis of PCT or HEP because the dermal histopathology is nonspecific and the diagnosis is made by documentation of biochemical abnormalities [<a href="#rid97">97</a>].</p><p>If performed, histopathology may show characteristic histologic features including subepidermal blisters and deposition of periodic-acid-Schiff (PAS) positive amorphous hyaline material containing immunoglobulin around vessel walls, with little inflammation unless there is secondary infection [<a href="#rid98">98</a>]. Similar histologic findings are seen in other cutaneous porphyrias and in pseudoporphyria, but a skin biopsy may exclude blistering due to diseases other than porphyrias and pseudoporphyria.</p><p class="headingAnchor" id="H2867289"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of PCT (or HEP) is made in an individual with current or prior blistering skin lesions by laboratory testing described above. (See <a class="local">'Blistering skin lesions and other cutaneous manifestations'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCT</strong> – The diagnosis of PCT requires documentation of the associated biochemical pattern of porphyrin increases, which includes increased plasma or urine porphyrins (especially uro-, hepta-, and to lesser extents, hexa-, and penta-carboxyl porphyrins); plasma peak fluorescence at approximately 620 nm; and little or no increase in erythrocyte porphyrins. Additional confirmation is provided by findings of normal (or mildly elevated) urinary ALA, normal urinary PBG, and normal or elevated fecal porphyrins (with a complex pattern including isocoproporphyrins).</p><p></p><p class="bulletIndent1">Molecular analysis to identify or exclude pathogenic variants in <em>UROD</em> and <em>HFE</em> is part of a complete assessment of susceptibility factors in PCT but is not required for diagnosis. Finding biallelic <em>HFE</em> variants favors treatment by phlebotomies to remove excess iron if the serum ferritin exceeds 100 ng/mL. (See  <a class="medical medical_review" href="/z/d/html/101414.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis", section on 'Overview of management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HEP</strong> – The diagnosis of HEP is made by documenting the same porphyrin increases as in PCT plus a marked increase in erythrocyte zinc protoporphyrin and should be confirmed by molecular studies that demonstrate pathogenic variants affecting both <em>UROD</em> alleles.</p><p></p><p class="headingAnchor" id="H2867411"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of PCT and HEP includes other blistering cutaneous porphyrias (differentiated as described above (see <a class="local">'Laboratory testing'</a> above)), other causes of blistering skin lesions, and other causes of porphyrin elevation in urine, plasma, or feces.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous porphyrias</strong> – Cutaneous porphyrias are divided into blistering and nonblistering.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blistering</strong> – Other blistering cutaneous porphyrias include variegate porphyria (VP), hereditary coproporphyria (HCP), congenital erythropoietic porphyria (CEP), autosomal dominant forms of acute hepatic porphyrias, and harderoporphyria (a variant form of homozygous HCP). These rare types of porphyria are commonly misdiagnosed as PCT, especially in adults, but they are readily differentiated by laboratory testing. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The cutaneous porphyrias listed above cause blistering lesions on sun-exposed skin, and porphyrin elevations in urine, plasma, and feces. Scarring is generally more severe in CEP than in PCT, but mild cases of CEP in adults are often initially misdiagnosed as having PCT. Unlike PCT and HEP, VP and HCP can cause acute neurovisceral attacks, although they can also present only with skin manifestations. Clear differentiation of the different types of blistering cutaneous porphyrias requires additional biochemical testing. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Unlike PCT, in which delta-aminolevulinic acid (ALA) may be slightly elevated and porphobilinogen (PBG) is always normal, in HCP and VP, ALA and PBG may be normal or substantially elevated. </p><p></p><p class="bulletIndent2">These differences are summarized in the table (<a class="graphic graphic_table graphicRef80601" href="/z/d/graphic/80601.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/7126.html" rel="external">"Variegate porphyria"</a> and  <a class="medical medical_review" href="/z/d/html/7100.html" rel="external">"Hereditary coproporphyria"</a> and  <a class="medical medical_review" href="/z/d/html/7102.html" rel="external">"Congenital erythropoietic porphyria"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonblistering</strong> – The nonblistering cutaneous porphyrias are erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Unlike other cutaneous porphyrias, EPP and XLP cause pain on sun-exposed areas of skin, often after a few minutes of sun exposure, which unless exposure ceases may be followed by swelling and erythema but little blistering or residual scarring. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>EPP and XLP, in contrast with PCT, cause substantial increases in erythrocyte total protoporphyrin (mostly metal-free rather than zinc-chelated) but do not increase urine porphyrins. (See  <a class="medical medical_review" href="/z/d/html/7125.html" rel="external">"Erythropoietic protoporphyria and X-linked protoporphyria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes of blistering skin lesions</strong> – A variety of nonporphyric conditions can cause blistering lesions on sun-exposed skin. Examples include polymorphous light eruptions, epidermolysis bullosa, pseudoporphyria, and phototoxic drug reactions and eruptions. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Like PCT, these conditions affect sun-exposed skin and some may cause scarring. Skin biopsy findings may help to differentiate some of these conditions. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unlike PCT (or other cutaneous porphyrias), these conditions are not associated with elevated total porphyrins in urine or plasma. </p><p></p><p class="bulletIndent1">These disorders and approaches to their evaluation and diagnosis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6623.html" rel="external">"Polymorphous light eruption"</a> and  <a class="medical medical_review" href="/z/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/13748.html" rel="external">"Pseudoporphyria"</a> and  <a class="medical medical_review" href="/z/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes of porphyrin elevation</strong> – Increased total porphyrins in urine, plasma (or serum), and/or feces can result from other cutaneous porphyrias, neurovisceral porphyrias, liver disease, certain drugs, and other medical conditions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurovisceral (acute) porphyrias</strong> – Neurovisceral (also called acute hepatic) porphyrias include ALA dehydratase porphyria (ADP), acute intermittent porphyria (AIP), HCP, and VP. </p><p></p><p class="bulletIndent2">Like PCT/HEP, these neurovisceral porphyrias may cause porphyrin elevations in urine, plasma, and feces, especially during or around the time of acute attacks of abdominal pain and/or neurologic symptoms (eg, extremity pain, seizures, motor weakness). However, neurologic or abdominal symptoms due to another cause sometimes occur in patients with subclinical PCT; diagnostic confusion is avoided in such cases by excluding acute porphyrias and obtaining clear biochemical documentation of PCT. (See  <a class="medical medical_review" href="/z/d/html/7095.html" rel="external">"ALA dehydratase porphyria"</a> and  <a class="medical medical_review" href="/z/d/html/7096.html" rel="external">"Acute intermittent porphyria: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7100.html" rel="external">"Hereditary coproporphyria"</a> and  <a class="medical medical_review" href="/z/d/html/7126.html" rel="external">"Variegate porphyria"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver disease</strong> – Liver disease can cause elevations in urine porphyrins, especially coproporphyrin, which normally undergoes both urinary and biliary excretion. When hepatobiliary excretion is impaired, more coproporphyrin is excreted in urine. </p><p></p><p class="bulletIndent2">Unlike PCT and HEP, patients with liver disease from other causes do not have the characteristic PCT skin lesions. (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other medical conditions</strong> – Numerous other medical conditions and drugs can cause nonspecific elevation of urinary porphyrins whereas plasma/serum porphyrins are less affected. Such effects of other diseases and medications on urine porphyrins have been little studied, so specific attributions are difficult. </p><p></p><p class="bulletIndent2">Advanced chronic kidney disease may cause slight elevations in plasma/serum porphyrins, and it may be unclear whether such elevations represent subclinical PCT. </p><p></p><p class="bulletIndent2">Rarely, hepatocellular tumors are associated with marked porphyrin elevations, but these cases were not described in enough detail to know if a deficiency in a heme biosynthetic pathway enzyme in the tumor itself was causative [<a href="#rid99">99,100</a>].</p><p></p><p class="headingAnchor" id="H4035591135"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119744.html" rel="external">"Society guideline links: Porphyria"</a>.)</p><p class="headingAnchor" id="H2770497975"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/119380.html" rel="external">"Patient education: Porphyria cutanea tarda (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H962869723"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biology and prevalence</strong> – Porphyria cutanea tarda (PCT) and hepatoerythropoietic porphyria (HEP) are cutaneous porphyrias caused by reduced activity of the heme biosynthetic enzyme uroporphyrinogen decarboxylase (UROD) (<a class="graphic graphic_figure graphicRef117995" href="/z/d/graphic/117995.html" rel="external">figure 1</a>). PCT is a hepatic porphyria that can be classified as sporadic (type 1, without an inherited pathogenic <em>UROD</em> variant; approximately 80 percent of cases) or familial (type 2, with a heterozygous <em>UROD</em> variant, approximately 20 percent). In both familial and sporadic disease, acquired or other inherited susceptibility factor(s) such as alcohol use, smoking, estrogen use, hemochromatosis (<em>HFE</em>) gene variants, hepatitis C virus (HCV) infection and HIV infection are required for the disease phenotype to manifest. Multiple factors contribute to the disease in individual patients. HEP is due to biallelic pathogenic variants in <em>UROD </em>and is exceedingly rare. HEP can present in children or adults depending on the degree of UROD deficiency. (See <a class="local">'Disease classification'</a> above and <a class="local">'Pathogenesis'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typical findings</strong> – PCT generally presents in adulthood. Typical features include chronic blistering photosensitivity, especially on the backs of the hands and other sun-exposed areas, which can lead to scarring, hirsutism, hyperpigmentation, and hypopigmentation. In severe cases, secondary infection can occur. Patients may have elevations in serum transaminases, but neurovisceral attacks do not occur. Manifestations of HEP are similar but more severe and often develop in early childhood. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – As with other porphyrias, the evaluation for PCT is done in a stepwise fashion, starting with measurement of plasma or urinary total porphyrins. Plasma and urine total porphyrins are elevated in PCT with a characteristic pattern; normal porphyrin levels exclude PCT and all other blistering cutaneous porphyrias. If total plasma or urine porphyrins are elevated, more extensive second-line testing follows to exclude less common porphyrias that can cause identical skin manifestations (<a class="graphic graphic_algorithm graphicRef89035" href="/z/d/graphic/89035.html" rel="external">algorithm 1</a>). (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confirmation of the diagnosis</strong> – The diagnosis of PCT is made by documenting the characteristic biochemical porphyrin profile, which includes increased plasma and urine porphyrins with a predominance of highly carboxylated porphyrins. Plasma peak fluorescence at 620 nm distinguishes PCT from variegate porphyria (VP). Total fecal porphyrins in PCT may be normal or modestly elevated with a characteristic pattern that includes isocoproporphyrins (<a class="graphic graphic_table graphicRef89036" href="/z/d/graphic/89036.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef60572" href="/z/d/graphic/60572.html" rel="external">table 1</a>). Erythrocyte porphyrins are normal or modestly elevated, in contrast with marked elevations found in HEP and other porphyrias with biallelic variants. Molecular analysis will reveal a pathogenic variant in <em>UROD</em> in only approximately 20 percent of individuals. The biochemical porphyrin profile in HEP is similar to PCT but often more marked, with marked elevation of erythrocyte zinc protoporphyrin. HEP should be confirmed by molecular studies that demonstrate biallelic <em>UROD</em> variants. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of PCT includes other blistering cutaneous porphyrias, other phototoxic skin disorders including pseudoporphyria. Urinary or plasma porphyrin elevations are also seen in other medical conditions. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Management and prognosis of PCT and HEP are presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/101414.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Management and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H29156639"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Waldenstrom J. Studien über porphyrie. Acta Med Scand 1937; Suppl82.</a></li><li><a class="nounderline abstract_t">Gunther H. Die hämatoporphyrie. Dtsh Arch Klin Med 1911; 105:89.</a></li><li><a class="nounderline abstract_t">Elder GH, Smith SG, Herrero C, et al. Hepatoerythropoietic porphyria: a new uroporphyrinogen decarboxylase defect or homozygous porphyria cutanea tarda? Lancet 1981; 1:916.</a></li><li><a class="nounderline abstract_t">Jalil S, Grady JJ, Lee C, Anderson KE. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol 2010; 8:297.</a></li><li><a class="nounderline abstract_t">Badenas C, To-Figueras J, Phillips JD, et al. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet 2009; 75:346.</a></li><li><a class="nounderline abstract_t">de Verneuil H, Sassa S, Kappas A. Purification and properties of uroporphyrinogen decarboxylase from human erythrocytes. A single enzyme catalyzing the four sequential decarboxylations of uroporphyrinogens I and III. J Biol Chem 1983; 258:2454.</a></li><li><a class="nounderline abstract_t">Jackson AH, Sancovich HA, Ferramola AM, et al. Macrocyclic intermediates in the biosynthesis of porphyrins. Philos Trans R Soc Lond B Biol Sci 1976; 273:191.</a></li><li class="breakAll">Elder GH. Porphyria cutanea tarda and related disorders. In: The Porphyrin Handbook, Kadish K, Smith K, Guilard R (Eds), Elsevier Science, San Diego 2003. Vol 14, p.67.</li><li class="breakAll">Phillips JD, Anderson KE. The porphyrias (Chapter 31). In: The red cell and its diseases, 1st ed, Lichtman MA, Prchal JT, Lichtman MA (Eds), McGraw-Hill, New York 2022. p.395.</li><li><a class="nounderline abstract_t">Magnus IA. Cutaneous porphyria. Clin Haematol 1980; 9:273.</a></li><li><a class="nounderline abstract_t">Lim HW, Poh-Fitzpatrick MB, Gigli I. Activation of the complement system in patients with porphyrias after irradiation in vivo. J Clin Invest 1984; 74:1961.</a></li><li><a class="nounderline abstract_t">Lim HW. Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria. Immunol Ser 1989; 46:671.</a></li><li><a class="nounderline abstract_t">Lançoni G, Ravinal RC, Costa RS, Roselino AM. Mast cells and transforming growth factor-beta expression: a possible relationship in the development of porphyria cutanea tarda skin lesions. Int J Dermatol 2008; 47:575.</a></li><li><a class="nounderline abstract_t">Meguro K, Fujita H, Ishida N, et al. Molecular defects of uroporphyrinogen decarboxylase in a patient with mild hepatoerythropoietic porphyria. J Invest Dermatol 1994; 102:681.</a></li><li><a class="nounderline abstract_t">Cantatore-Francis JL, Cohen-Pfeffer J, Balwani M, et al. Hepatoerythropoietic porphyria misdiagnosed as child abuse: cutaneous, arthritic, and hematologic manifestations in siblings with a novel UROD mutation. Arch Dermatol 2010; 146:529.</a></li><li><a class="nounderline abstract_t">Méndez M, Poblete-Gutiérrez P, García-Bravo M, et al. Molecular heterogeneity of familial porphyria cutanea tarda in Spain: characterization of 10 novel mutations in the UROD gene. Br J Dermatol 2007; 157:501.</a></li><li><a class="nounderline abstract_t">Garey JR, Hansen JL, Harrison LM, et al. A point mutation in the coding region of uroporphyrinogen decarboxylase associated with familial porphyria cutanea tarda. Blood 1989; 73:892.</a></li><li><a class="nounderline abstract_t">McManus JF, Begley CG, Sassa S, Ratnaike S. Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria. Blood 1996; 88:3589.</a></li><li><a class="nounderline abstract_t">Moran-Jimenez MJ, Ged C, Romana M, et al. Uroporphyrinogen decarboxylase: complete human gene sequence and molecular study of three families with hepatoerythropoietic porphyria. Am J Hum Genet 1996; 58:712.</a></li><li><a class="nounderline abstract_t">Mendez M, Sorkin L, Rossetti MV, et al. Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles. Am J Hum Genet 1998; 63:1363.</a></li><li><a class="nounderline abstract_t">Phillips JD, Whitby FG, Stadtmueller BM, et al. Two novel uroporphyrinogen decarboxylase (URO-D) mutations causing hepatoerythropoietic porphyria (HEP). Transl Res 2007; 149:85.</a></li><li><a class="nounderline abstract_t">Phillips JD, Bergonia HA, Reilly CA, et al. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A 2007; 104:5079.</a></li><li><a class="nounderline abstract_t">Gorman N, Zaharia A, Trask HS, et al. Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda. Hepatology 2007; 46:1927.</a></li><li><a class="nounderline abstract_t">Nakano K, Ishizuka M, Sakamoto KQ, Fujita S. Absolute requirement for iron in the development of chemically induced uroporphyria in mice treated with 3-methylcholanthrene and 5-aminolevulinate. Biometals 2009; 22:345.</a></li><li><a class="nounderline abstract_t">Ajioka RS, Phillips JD, Weiss RB, et al. Down-regulation of hepcidin in porphyria cutanea tarda. Blood 2008; 112:4723.</a></li><li><a class="nounderline abstract_t">Turnbull A, Baker H, Vernon-Roberts B, Magnus IA. Iron metabolism in porphyria cutanea tarda and in erythropoietic protoporphyria. Q J Med 1973; 42:341.</a></li><li><a class="nounderline abstract_t">Grossman ME, Bickers DR, Poh-Fitzpatrick MB, et al. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am J Med 1979; 67:277.</a></li><li><a class="nounderline abstract_t">Stölzel U, Köstler E, Koszka C, et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995; 21:1500.</a></li><li><a class="nounderline abstract_t">Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27:1661.</a></li><li><a class="nounderline abstract_t">HALLEN J, KROOK H. Follow-up studies on an unselected ten-year material of 360 patients with liver cirrhosis in one community. Acta Med Scand 1963; 173:479.</a></li><li><a class="nounderline abstract_t">Harrison-Findik DD, Klein E, Crist C, et al. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 2007; 46:1979.</a></li><li><a class="nounderline abstract_t">Ohtake T, Saito H, Hosoki Y, et al. Hepcidin is down-regulated in alcohol loading. Alcohol Clin Exp Res 2007; 31:S2.</a></li><li><a class="nounderline abstract_t">Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003; 39:620.</a></li><li><a class="nounderline abstract_t">Younossi Z, Park H, Henry L, et al. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology 2016; 150:1599.</a></li><li><a class="nounderline abstract_t">Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123:615.</a></li><li><a class="nounderline abstract_t">Sinclair PR, Bement WJ, Bonkovsky HL, Sinclair JF. Inhibition of uroporphyrinogen decarboxylase by halogenated biphenyls in chick hepatocyte cultures. Essential role for induction of cytochrome P-448. Biochem J 1984; 222:737.</a></li><li><a class="nounderline abstract_t">Smith AG, Francis JE. Chemically-induced formation of an inhibitor of hepatic uroporphyrinogen decarboxylase in inbred mice with iron overload. Biochem J 1987; 246:221.</a></li><li><a class="nounderline abstract_t">Korenaga M, Okuda M, Otani K, et al. Mitochondrial dysfunction in hepatitis C. J Clin Gastroenterol 2005; 39:S162.</a></li><li><a class="nounderline abstract_t">Miura K, Taura K, Kodama Y, et al. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008; 48:1420.</a></li><li><a class="nounderline abstract_t">Sastre L, To-Figueras J, Lens S, et al. Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals. Aliment Pharmacol Ther 2020; 51:968.</a></li><li><a class="nounderline abstract_t">Bonkovsky HL, Rudnick SP, Ma CD, et al. Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C. Dig Dis Sci 2023; 68:2738.</a></li><li><a class="nounderline abstract_t">Wissel PS, Sordillo P, Anderson KE, et al. Porphyria cutanea tarda associated with the acquired immune deficiency syndrome. Am J Hematol 1987; 25:107.</a></li><li><a class="nounderline abstract_t">Drobacheff C, Derancourt C, Van Landuyt H, et al. Porphyria cutanea tarda associated with human immunodeficiency virus infection. Eur J Dermatol 1998; 8:492.</a></li><li><a class="nounderline abstract_t">Castanet J, Lacour JP, Bodokh J, et al. Porphyria cutanea tarda in association with human immunodeficiency virus infection: it is related to hepatitis C virus infection? Arch Dermatol 1994; 130:664.</a></li><li><a class="nounderline abstract_t">Mansourati FF, Stone VE, Mayer KH. Porphyria cutanea tarda and HIV/AIDS: a review of pathogenesis, clinical manifestations and management. Int J STD AIDS 1999; 10:51.</a></li><li><a class="nounderline abstract_t">Aguilera P, Laguno M, To-Figueras J. Human immunodeficiency virus and risk of porphyria cutanea tarda: a possible association examined in a large hospital. Photodermatol Photoimmunol Photomed 2016; 32:93.</a></li><li><a class="nounderline abstract_t">Rajka G. Pregnancy and porphyria cutanea tarda. Acta Derm Venereol 1984; 64:444.</a></li><li><a class="nounderline abstract_t">Goerz G, Hammer G. Porphyria cutanea tarda and pregnancy. Dermatologica 1983; 166:316.</a></li><li><a class="nounderline abstract_t">Egger NG, Goeger DE, Payne DA, et al. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002; 47:419.</a></li><li><a class="nounderline abstract_t">Roenigk HH Jr, Gottlob ME. Estrogen-induced porphyria cutanea tarda. Report of three cases. Arch Dermatol 1970; 102:260.</a></li><li><a class="nounderline abstract_t">Wang MY, Liehr JG. Identification of fatty acid hydroperoxide cofactors in the cytochrome P450-mediated oxidation of estrogens to quinone metabolites. Role and balance of lipid peroxides during estrogen-induced carcinogenesis. J Biol Chem 1994; 269:284.</a></li><li><a class="nounderline abstract_t">Fontanellas A, Martínez-Fresno M, Garrido-Astray MC, et al. Smoking but not homozygosity for CYP1A2 g-163A allelic variant leads to earlier disease onset in patients with sporadic porphyria cutanea tarda. Exp Dermatol 2010; 19:e326.</a></li><li><a class="nounderline abstract_t">Christiansen L, Bygum A, Jensen A, et al. Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum Genet 2000; 107:612.</a></li><li><a class="nounderline abstract_t">Wickliffe JK, Abdel-Rahman SZ, Lee C, et al. CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. Mol Med 2011; 17:241.</a></li><li><a class="nounderline abstract_t">Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000; 95:1565.</a></li><li><a class="nounderline abstract_t">Stuart KA, Busfield F, Jazwinska EC, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998; 28:404.</a></li><li><a class="nounderline abstract_t">Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007; 46:1071.</a></li><li><a class="nounderline abstract_t">McLaren CE, Emond MJ, Subramaniam VN, et al. Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload. Hepatology 2015; 62:429.</a></li><li><a class="nounderline abstract_t">Farrell CP, Overbey JR, Naik H, et al. The D519G Polymorphism of Glyceronephosphate O-Acyltransferase Is a Risk Factor for Familial Porphyria Cutanea Tarda. PLoS One 2016; 11:e0163322.</a></li><li><a class="nounderline abstract_t">Rossmann-Ringdahl I, Olsson R. Porphyria cutanea tarda in a Swedish population: risk factors and complications. Acta Derm Venereol 2005; 85:337.</a></li><li><a class="nounderline abstract_t">Lee SC, Yun SJ, Lee JB, et al. A case of porphyria cutanea tarda in association with idiopathic myelofibrosis and CREST syndrome. Br J Dermatol 2001; 144:182.</a></li><li><a class="nounderline abstract_t">Anderson KE, Goeger DE, Carson RW, et al. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med 1990; 322:315.</a></li><li><a class="nounderline abstract_t">Seubert S, Seubert A, Rumpf KW, Kiffe H. A porphyria cutanea tarda-like distribution pattern of porphyrins in plasma, hemodialysate, hemofiltrate, and urine of patients on chronic hemodialysis. J Invest Dermatol 1985; 85:107.</a></li><li><a class="nounderline abstract_t">SCHMID R. Acquired porphyria. JAMA 1963; 183:133.</a></li><li><a class="nounderline abstract_t">CAN C, NIGOGOSYAN G. Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. Report of 348 cases caused by this fungicide. JAMA 1963; 183:88.</a></li><li><a class="nounderline abstract_t">Jones RE, Chelsky M. Further discussion concerning porphyria cutanea tarda and TCDD exposure. Arch Environ Health 1986; 41:100.</a></li><li><a class="nounderline abstract_t">Collins AG, Nichol AW, Elsbury S. Porphyria cutanea tarda and agricultural pesticides. Australas J Dermatol 1982; 23:70.</a></li><li><a class="nounderline abstract_t">Bleakley P, Nichol AW, Collins AG. Diazinon and porphyria cutanea tarda. Med J Aust 1979; 1:314.</a></li><li class="breakAll">Harber LC, Bickers DR. Photosensitivity diseases: principles of diagnosis and treatment, WB Saunders, Philadelphia 1981. p.189.</li><li><a class="nounderline abstract_t">Mykletun M, Aarsand AK, Støle E, et al. Porphyrias in Norway. Tidsskr Nor Laegeforen 2014; 134:831.</a></li><li><a class="nounderline abstract_t">Brady JJ, Jackson HA, Roberts AG, et al. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol 2000; 115:868.</a></li><li><a class="nounderline abstract_t">Horina JH, Wolf P. Epoetin for severe anemia in hepatoerythropoietic porphyria. N Engl J Med 2000; 342:1294.</a></li><li><a class="nounderline abstract_t">Mascaro JM. The porphyrias: a brief overview based on 25 years of experience (1969-1994) by the Department of Dermatology of the Hospital Clinic and Faculty of Medicine of Barcelona, Spain. J Dermatol 1995; 22:823.</a></li><li><a class="nounderline abstract_t">Andersen J, Gjengedal E, Sandberg S, Råheim M. A skin disease, a blood disease or something in between? An exploratory focus group study of patients' experiences with porphyria cutanea tarda. Br J Dermatol 2015; 172:223.</a></li><li><a class="nounderline abstract_t">Khayat R, Dupuy A, Pansé I, et al. [Sclerodermatous changes in porphyria cutanea tarda: six cases]. Ann Dermatol Venereol 2013; 140:589.</a></li><li><a class="nounderline abstract_t">Stevens HP, Ostlere LS, Black CM, Rustin MH. Generalized morphoea secondary to porphyria cutanea tarda. Br J Dermatol 1993; 129:455.</a></li><li><a class="nounderline abstract_t">Andersen J, Thomsen J, Enes ÅR, et al. Health-related quality of life in porphyria cutanea tarda: a cross-sectional registry based study. Health Qual Life Outcomes 2020; 18:84.</a></li><li><a class="nounderline abstract_t">Cortés JM, Oliva H, Paradinas FJ, Hernandez-Guío C. The pathology of the liver in porphyria cutanea tarda. Histopathology 1980; 4:471.</a></li><li><a class="nounderline abstract_t">Kordac V. Frequency of occurrence of hepatocellular carcinoma in patients with porphyria cutanea tarda in long-term follow-up. Neoplasma 1972; 19:135.</a></li><li><a class="nounderline abstract_t">Linet MS, Gridley G, Nyrén O, et al. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol 1999; 149:1010.</a></li><li><a class="nounderline abstract_t">Fakan F, Chlumská A. Demonstration of needle-shaped hepatic inclusions in porphyria cutanea tarda using the ferric ferricyanide reduction test. Virchows Arch A Pathol Anat Histopathol 1987; 411:365.</a></li><li><a class="nounderline abstract_t">Chlumska A, Chlumsky J, Malina L. Liver changes in porphyria cutanea tarda patients treated with chloroquine. Br J Dermatol 1980; 102:261.</a></li><li><a class="nounderline abstract_t">Bygum A, Brandrup F. Iron overload in porphyria cutanea tarda. Br J Dermatol 2000; 143:1116.</a></li><li><a class="nounderline abstract_t">Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003; 30:137.</a></li><li><a class="nounderline abstract_t">Lundvall O, Weinfeld A, Lundin P. Iron storage in porphyria cutanea tarda. Acta Med Scand 1970; 1-2:37.</a></li><li><a class="nounderline abstract_t">Elder GH. Porphyrin metabolism in porphyria cutanea tarda. Semin Hematol 1977; 14:227.</a></li><li><a class="nounderline abstract_t">Sampietro M, Fiorelli G, Fargion S. Iron overload in porphyria cutanea tarda. Haematologica 1999; 84:248.</a></li><li><a class="nounderline abstract_t">Dereure O, Jumez N, Bessis D, et al. Measurement of liver iron content by magnetic resonance imaging in 20 patients with overt porphyria cutanea tarda before phlebotomy therapy: a prospective study. Acta Derm Venereol 2008; 88:341.</a></li><li><a class="nounderline abstract_t">Anderson KE, Goeger DE, Bessman JD. Asymptomatic erythrocyte disorder presenting as increased porphobilinogen deaminase and uroporphyrinogen decarboxylase. Clin Chem 1995; 41:1670.</a></li><li><a class="nounderline abstract_t">Day RS, Strauss PC. Severe cutaneous porphyria in a 12-year-old boy: hepatoerythropoietic or symptomatic porphyria? Arch Dermatol 1982; 118:663.</a></li><li><a class="nounderline abstract_t">Deacon AC, Elder GH. ACP Best Practice No 165: front line tests for the investigation of suspected porphyria. J Clin Pathol 2001; 54:500.</a></li><li><a class="nounderline abstract_t">Hindmarsh JT, Oliveras L, Greenway DC. Plasma porphyrins in the porphyrias. Clin Chem 1999; 45:1070.</a></li><li><a class="nounderline abstract_t">Lim HW, Poh-Fitzpatrick MB. Hepatoerythropoietic porphyria: a variant of childhood-onset porphyria cutanea tarda. Porphyrin profiles and enzymatic studies of two cases in a family. J Am Acad Dermatol 1984; 11:1103.</a></li><li><a class="nounderline abstract_t">Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol 2006; 135:281.</a></li><li><a class="nounderline abstract_t">Boudghène-Stambouli O, Mérad-Boudia A. [Hepato-erythropoietic porphyria]. Ann Dermatol Venereol 1995; 122:615.</a></li><li><a class="nounderline abstract_t">Day RS, Eales L, Meissner D. Coexistent variegate porphyria and porphyria cutanea tarda. N Engl J Med 1982; 307:36.</a></li><li><a class="nounderline abstract_t">Bajaj D, Pachyala A, Singal AK. Porphyria cutanea tarda is a biochemical and not histological diagnosis. Gastroenterol Hepatol Open Access 2016; 5.</a></li><li><a class="nounderline abstract_t">Maynard B, Peters MS. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol 1992; 19:40.</a></li><li><a class="nounderline abstract_t">O'Reilly K, Snape J, Moore MR. Porphyria cutanea tarda resulting from primary hepatocellular carcinoma. Clin Exp Dermatol 1988; 13:44.</a></li><li><a class="nounderline abstract_t">Ochiai T, Morishima T, Kondo M. Symptomatic porphyria secondary to hepatocellular carcinoma. Br J Dermatol 1997; 136:129.</a></li></ol></div><div id="topicVersionRevision">Topic 7108 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Studienüber porphyrie</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Die hämatoporphyrie</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6112327" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hepatoerythropoietic porphyria: a new uroporphyrinogen decarboxylase defect or homozygous porphyria cutanea tarda?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19948245" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Associations among behavior-related susceptibility factors in porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19419417" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6822570" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Purification and properties of uroporphyrinogen decarboxylase from human erythrocytes. A single enzyme catalyzing the four sequential decarboxylations of uroporphyrinogens I and III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4837" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Macrocyclic intermediates in the biosynthesis of porphyrins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4837" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Macrocyclic intermediates in the biosynthesis of porphyrins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4837" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Macrocyclic intermediates in the biosynthesis of porphyrins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7398149" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cutaneous porphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6392339" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Activation of the complement system in patients with porphyrias after irradiation in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2488874" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477147" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mast cells and transforming growth factor-beta expression: a possible relationship in the development of porphyria cutanea tarda skin lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8176248" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Molecular defects of uroporphyrinogen decarboxylase in a patient with mild hepatoerythropoietic porphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20479301" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hepatoerythropoietic porphyria misdiagnosed as child abuse: cutaneous, arthritic, and hematologic manifestations in siblings with a novel UROD mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17627795" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Molecular heterogeneity of familial porphyria cutanea tarda in Spain: characterization of 10 novel mutations in the UROD gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2920211" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A point mutation in the coding region of uroporphyrinogen decarboxylase associated with familial porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8896428" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644733" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Uroporphyrinogen decarboxylase: complete human gene sequence and molecular study of three families with hepatoerythropoietic porphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9792863" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17240319" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Two novel uroporphyrinogen decarboxylase (URO-D) mutations causing hepatoerythropoietic porphyria (HEP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17360334" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17854053" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18956144" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Absolute requirement for iron in the development of chemically induced uroporphyria in mice treated with 3-methylcholanthrene and 5-aminolevulinate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809758" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Down-regulation of hepcidin in porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4785438" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Iron metabolism in porphyria cutanea tarda and in erythropoietic protoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/463934" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539393" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620340" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13952160" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Follow-up studies on an unselected ten-year material of 360 patients with liver cirrhosis in one community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17763462" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17331161" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hepcidin is down-regulated in alcohol loading.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12971974" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26924097" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7677303" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6435605" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Inhibition of uroporphyrinogen decarboxylase by halogenated biphenyls in chick hepatocyte cultures. Essential role for induction of cytochrome P-448.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3675556" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Chemically-induced formation of an inhibitor of hepatic uroporphyrinogen decarboxylase in inbred mice with iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15758653" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mitochondrial dysfunction in hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18671304" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32294804" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36811718" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3578259" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Porphyria cutanea tarda associated with the acquired immune deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854161" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Porphyria cutanea tarda associated with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910010" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Porphyria cutanea tarda in association with human immunodeficiency virus infection: it is related to hepatitis C virus infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10215132" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Porphyria cutanea tarda and HIV/AIDS: a review of pathogenesis, clinical manifestations and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26576928" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Human immunodeficiency virus and risk of porphyria cutanea tarda: a possible association examined in a large hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6208730" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pregnancy and porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6884554" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Porphyria cutanea tarda and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11855561" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5456016" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Estrogen-induced porphyria cutanea tarda. Report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8276808" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Identification of fatty acid hydroperoxide cofactors in the cytochrome P450-mediated oxidation of estrogens to quinone metabolites. Role and balance of lipid peroxides during estrogen-induced carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20163457" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Smoking but not homozygosity for CYP1A2 g-163A allelic variant leads to earlier disease onset in patients with sporadic porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11153915" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20957336" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10688809" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551677" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17828789" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605615" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27661980" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The D519G Polymorphism of Glyceronephosphate O-Acyltransferase Is a Risk Factor for Familial Porphyria Cutanea Tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16191856" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Porphyria cutanea tarda in a Swedish population: risk factors and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11167703" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A case of porphyria cutanea tarda in association with idiopathic myelofibrosis and CREST syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2104958" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4020158" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A porphyria cutanea tarda-like distribution pattern of porphyrins in plasma, hemodialysate, hemofiltrate, and urine of patients on chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13991941" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Acquired porphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14018209" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. Report of 348 cases caused by this fungicide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3521500" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Further discussion concerning porphyria cutanea tarda and TCDD exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6185111" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Porphyria cutanea tarda and agricultural pesticides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/449807" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Diazinon and porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/449807" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diazinon and porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24780981" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Porphyrias in Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069625" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10787339" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Epoetin for severe anemia in hepatoerythropoietic porphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8557853" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The porphyrias: a brief overview based on 25 years of experience (1969-1994) by the Department of Dermatology of the Hospital Clinic and Faculty of Medicine of Barcelona, Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24958197" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A skin disease, a blood disease or something in between? An exploratory focus group study of patients' experiences with porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24090888" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : [Sclerodermatous changes in porphyria cutanea tarda: six cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8105868" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Generalized morphoea secondary to porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32228630" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Health-related quality of life in porphyria cutanea tarda: a cross-sectional registry based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6253381" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The pathology of the liver in porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4336890" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Frequency of occurrence of hepatocellular carcinoma in patients with porphyria cutanea tarda in long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10355376" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2820121" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Demonstration of needle-shaped hepatic inclusions in porphyria cutanea tarda using the ferric ferricyanide reduction test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7370174" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Liver changes in porphyria cutanea tarda patients treated with chloroquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069545" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Iron overload in porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12957298" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Iron as a co-morbid factor in nonhemochromatotic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5507243" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Iron storage in porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/323985" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Porphyrin metabolism in porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10189391" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Iron overload in porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18709302" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Measurement of liver iron content by magnetic resonance imaging in 20 patients with overt porphyria cutanea tarda before phlebotomy therapy: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586564" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Asymptomatic erythrocyte disorder presenting as increased porphobilinogen deaminase and uroporphyrinogen decarboxylase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7114869" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Severe cutaneous porphyria in a 12-year-old boy: hepatoerythropoietic or symptomatic porphyria?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11429419" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : ACP Best Practice No 165: front line tests for the investigation of suspected porphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10388484" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Plasma porphyrins in the porphyrias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6512055" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Hepatoerythropoietic porphyria: a variant of childhood-onset porphyria cutanea tarda. Porphyrin profiles and enzymatic studies of two cases in a family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16956347" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Modern diagnosis and management of the porphyrias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8745689" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : [Hepato-erythropoietic porphyria].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7078623" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Coexistent variegate porphyria and porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Porphyria cutanea tarda is a biochemical and not histological diagnosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1556265" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Histologic and immunofluorescence study of cutaneous porphyrias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2850121" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Porphyria cutanea tarda resulting from primary hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039312" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Symptomatic porphyria secondary to hepatocellular carcinoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
